New anti-obesity drug Liraglutide significantly reduce weight

The drug, liraglutide, is the first of a new class of anti-obesity agents which mimic the action of a hormone that occurs naturally in the gut, reducing hunger. Experts said it had "great potential" because it also reduced the risk factors for Type 2 diabetes and heart disease. Diabetes already affects more than two million people in Britain and is rising so fast it threatens to overwhelm the National Health Service (NHS). "It tells the body to produce more insulin and the brain to stop eating. It is a naturally occurring satiety hormone. "The problem is that it is eliminated from the blood stream within minutes. The company (Novo Nordisk) has added a molecule to make it more resistant to elimination, so it lasts for a full day." Read more: NZHerald